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Abstract
Introduction: Succinylcholine and rocuronium are widely used to facilitate rapid sequence induction (RSI) intubation
in intensive care. Concerns relate to the side effects of succinylcholine and to slower onset and inferior intubation
conditions associated with rocuronium. So far, succinylcholine and rocuronium have not been compared in an
adequately powered randomized trial in intensive care. Accordingly, the aim of the present study was to compare the
incidence of hypoxemia after rocuronium or succinylcholine in critically ill patients requiring an emergent RSI.
Methods: This was a prospective randomized controlled single-blind trial conducted from 2006 to 2010 at the
University Hospital of Basel. Participants were 401 critically ill patients requiring emergent RSI. Patients were
randomized to receive 1 mg/kg succinylcholine or 0.6 mg/kg rocuronium for neuromuscular blockade. The primary
outcome was the incidence of oxygen desaturations defined as a decrease in oxygen saturation ≥ 5%, assessed by
continuous pulse oxymetry, at any time between the start of the induction sequence and two minutes after the
completion of the intubation. A severe oxygen desaturation was defined as a decrease in oxygen saturation ≥ 5%
leading to a saturation value of ≤ 80%.
Results: There was no difference between succinylcholine and rocuronium regarding oxygen desaturations
(succinylcholine 73/196; rocuronium 66/195; P = 0.67); severe oxygen desaturations (succinylcholine 20/196; rocuronium
20/195; P = 1.0); and extent of oxygen desaturations (succinylcholine -14 ± 12%; rocuronium -16 ± 13%; P = 0.77). The
duration of the intubation sequence was shorter after succinycholine than after rocuronium (81 ± 38 sec versus 95 ± 48
sec; P = 0.002). Intubation conditions (succinylcholine 8.3 ± 0.8; rocuronium 8.2 ± 0.9; P = 0.7) and failed first intubation
attempts (succinylcholine 32/200; rocuronium 36/201; P = 1.0) did not differ between the groups.
Conclusions: In critically ill patients undergoing emergent RSI, incidence and severity of oxygen desaturations, the
quality of intubation conditions, and incidence of failed intubation attempts did not differ between succinylcholine
and rocuronium.
Trial Registration: ClinicalTrials.gov, number NCT00355368.
Introduction
Endotracheal intubation in critically ill patients is a high
risk procedure containing the danger of hypoxia and
cardiovascular collapse. The method of choice for emer-
gency intubation in the intensive care unit (ICU) is a
rapid sequence induction (RSI). Because of its fast onset,
succinylcholine is the most commonly used neuromus-
cular blocking drug in RSI. Due to its depolarizing
mechanism of action resulting in an increase in extracel-
lular potassium, succinylcholine is contraindicated in a
number of circumstances and diseases frequently pre-
sent in critically ill patients [1]. Rocuronium has the
most rapid onset of the currently available non-depolar-
izing neuromuscular blocking drugs. As the only contra-
indication to rocuronium is the very rare occasion of
allergy, this agent is regarded as an attractive alternative
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any medium, provided the original work is properly cited.to succinylcholine [2,3]. Assessing current clinical prac-
tice by analyzing large contemporary trials reveals a
wide variation in the use of rocuronium or succinylcho-
line for RSI in the ICU [4-8]. However, neither agent
has been so far tested against each other or any other
neuromuscular blocking agent in an adequately powered
randomized trial in critically ill patients.
Compared to succinylcholine, rocuronium is asso-
ciated with less optimal intubation conditions [3,9] and
a longer intubation sequence [9] in the operating thea-
tre. As the most frequent complication of RSI in the
ICU is severe hypoxemia [4,7] the combination of less
optimal intubation conditions and longer intubation
sequence may be of relevance. Given the low rate of
hypoxemia during RSI in the operating theatre, available
studies are underpowered for this outcome. The aim of
this prospective randomized controlled trial was, there-
f o r e ,t oc o m p a r et h ei n c i d e n c eo fh y p o x e m i aa f t e r
rocuronium or succinylcholine in critically ill patients
requiring an emergent RSI.
Material and methods
Design
This is a prospective randomized controlled single-blind
trial. The trial is registered, ClinicalTrials.gov, number
NCT00355368.
Setting
The trial took place in the medical and surgical ICUs of
the University Hospital of Basel, a tertiary care center.
Patients
All adult (age ≥ 18 years) patients requiring emergent
endotracheal intubation with a RSI were eligible. The
indication for intubation was made by the staff physician
in charge of the patient’s care. Patients could be
included only once in the trial. Exclusion criteria were
contraindications against succinylcholine (that is, hyper-
kalemia, neuromuscular diseases, denervation of mus-
cles, tetraplegia, long-term immobilization, extensive
muscle trauma, burns, familial history of malignant
hyperthermia), allergy to rocuronium, pregnancy, known
or anticipated difficult intubation warranting awake
fiberoptic intubation, and absence of a qualified study
physician to perform the intubation. Patients excluded
from the study because of the absence of a qualified
study physician and those erroneously included more
than once were included in a registry. Acute Physiology
And Chronic Health Evaluation II (APACHE II) scores
[10] were calculated for each patient based on the 24
hours preceding intubation.
The study was conducted in compliance with the Hel-
sinki Declaration and was approved by the regional
Ethics Committee (Ethikkommission beider Basel, Basel,
Switzerland). Because critically ill patients requiring an
emergent intubation are typically unable to give
informed consent, the regional Ethics Committee
granted a waiver of consent prior to the intubation.
Instead, investigators were obliged to inform relatives
and obtain written informed consent from patients as
soon as feasible.
Intervention
Stratified randomization by gender was used to ensure a
similar distribution of gender in both groups. Using
sealed envelopes, patients were randomly allocated by
the study physician to receive either 0.6 mg/kg rocuro-
nium (Esmeron
®, Organon, Pfäffikon, Switzerland) or
1.0 mg/kg succinylcholine (Lystenon
®, Nycomed, Opfi-
kon, Switzerland) intravenously as neuromuscular block-
ing drug.
Preparations for intubation followed a checklist
(Additional file 1). Intubations were performed or
supervised by a study physician, defined as a physician
with dual training in anaesthesia (board certified) and
critical care (board certified or in the last year of train-
ing). The pre-intubation management including the
position of the head of the bed (horizontal or ele-
vated), the application of cricoid pressure [11], and the
management of difficulties and complications, if any,
was at the discretion of the study physicians. The pro-
tocol encouraged, time permitting, cardiovascular opti-
mization prior to intubation using fluids and
catecholamine infusion. In patients undergoing non-
invasive ventilation, the protocol encouraged continued
non-invasive ventilation with 100% oxygen as the
means of pre-oxygenation. All other patients were pre-
oxygenated using a bag-mask device with high flow
oxygen. Patients receiving light sedation to tolerate
non-invasive ventilation continued to do so until the
beginning of the induction sequence.
A total of 1 μg/kg intravenous fentanyl was adminis-
tered at the beginning of the three-minute pre-oxygena-
tion period. Thereafter, an intravenous induction agent
was administered: etomidate 0.2 mg/kg in patients with
a mean arterial pressure < 80 mmHg and/or a catecho-
lamine infusion; propofol 1 mg/kg in all other patients.
The neuromuscular blocking drug was injected as soon
as the injection of the induction agent was completed.
Laryngoscopy was started after the cessation of fascicu-
lations in the lower extremities [12], if any, or after 45
sec (anticipated time of intubation 60 sec after the injec-
tion of the neuromuscular blocking drug), whichever
was earlier. Intubations were performed using a Macin-
tosh size 3 blade and a tracheal tube (Mallinckrodt Hi-
Contour, Mallinckrodt, Ireland) with an internal dia-
meter of 8.0 cm. The timing of events was performed
using a stopwatch.
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The primary outcome was the incidence of oxygen desa-
turations defined as a decrease in oxygen saturation ≥
5%, assessed by continuous pulse oxymetry, at any time
between the start of the induction sequence and two
minutes after the completion of the intubation. A severe
oxygen desaturation was defined as a decrease in oxygen
saturation of ≥ 5% leading to a saturation value of ≤
80%.
Secondary outcomes were 1) the duration of the intu-
bation sequence, defined as the time interval between
the injection of the induction agent and the first appear-
ance of end-tidal carbon dioxide on the screen of the
monitor; 2) the incidence of failed first intubation
attempts; 3) numerical [2] and qualitative [13] intuba-
tion conditions as rated by the intubating study physi-
cian using a scoring system proposed for good clinical
research practice in studies of neuromuscular blocking
drugs [14] (Table 1); and 4) haemodynamic conse-
quences of intubation between the start of the induction
sequence and five minutes after the completion of the
intubation.
Statistical analysis
Data, presented as means ± SD unless otherwise stated,
were analyzed using SPSS 15.0 for Windows (SPPS Inc.,
Chicago, IL, USA). Two-way ANOVA, unpaired Stu-
dent’s t-test, Mann-Whitney test, Fisher’s exact test and
the logrank test were applied as appropriate. Based on
data from the literature we estimated that approximately
250 patients were required for each study group to
detect a difference of 20% in the primary outcome, inci-
dence of oxygen desaturation ≥ 5%, with a power of 0.9
and a two-sided a of 0.05. A planned interim power
analysis, performed with the results of the first 100
patients of the succinylcholine group, revealed that, in
fact, approximately 200 patients were required for each
study group. To account for protocol violations related
to an emergent procedure we planned to enroll 210
patients per group.
Results
The study started in August 2006 and ended with the
inclusion of the 420
th patient in June 2010. Figure 1
shows the patients’ flow. Of the 401 intubations 333
(83%) were accomplished on the first, 57 (14.2%) on the
second, 9 (2.2%) on the third, and 2 (0.5%) on the fourth
attempt. No periprocedural death occurred. Table 2
shows the indications for the intubations performed.
Demographics of the patients included in the study and
the registry are shown in Table 3.
Primary outcome
Due to a severe shock state, pulse oxymetry could not
measure oxygen saturation in four patients of the suc-
cinylcholine group and in six patients of the rocuro-
nium group. In the remaining patients, there was no
significant difference in the incidence of oxygen desa-
turations (succinylcholine 73/196 = 37%; rocuronium
66/195 = 34%; P = 0.67) and severe oxygen desatura-
tions (succinylcholine 20/196 = 10%; rocuronium 20/
195 = 10%; P = 1.0) between the groups. In those
patients exhibiting a decrease in oxygen saturation ≥
5%, there was no difference between the groups with
regard to the extent of the decrease (succinylcholine
-14 ± 12%; rocuronium -16 ± 13%; P = 0.77). Figure 2
displays the course of the oxygen saturation over the
intubation period.
Table 1 Scoring system for intubation conditions
Score 3 Score 2 Score 1
Laryngoscopy
Jaw relaxation Relaxed Acceptable relaxation Poor relaxation
Resistance to blade None Slight resistance Active resistance
Vocal cords
Position Abducted Intermediate Closed
Movement None Moving Closing
Intubation response
Limb movement None Slight Vigorous
Coughing None Diaphragmatic Severe coughing or bucking
Table 1 shows the scoring system used to derive both a numerical and qualitative intubation score. The factors laryngoscopy, vocal cords, and responset o
intubation are individually rated with a score from 1 (worst) to 3 (best). The assignment of a score for each of the three factors is based on the lower rating of
two parameters. For example, the combination of the parameters “no limb movement” and “no coughing” results in a score of 3 for the factor response to
intubation, while the combination of the parameters “no limb movement” and “severe coughing” results in a score of 1.
The numerical intubation score was obtained by summing up the scores assigned to the factors: laryngoscopy, vocal cords, and response to intubation. The
maximum score is thus 9, while the minimum score is 3.
The qualitative intubation scores were defined as follows: (a) Excellent intubation conditions: all three factors were rated with a score of 3. (b) Good intubation
conditions: all three factors were rated either with a score of 3 or 2. (c) Poor intubation conditions: the presence of one factor rated with a score of 1.
Excellent and good intubation conditions are considered clinically acceptable while poor intubation conditions are considered clinically not acceptable [14].
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More than one intubation attempt was required in 32/
200 patients under succinylcholine and in 36/201
patients under rocuronium (P = 0.4; Table 3). In 77/200
(39%) patients of the succinylcholine group fascicula-
tions were not visible or had not ceased 45 sec after the
injection of the drug. Figure 3 depicts the duration of
the intubation sequence which was significantly shorter
(P = 0.002) in the succinylcholine group (81 ± 38 sec)
than in the rocuronium group (95 ± 48 sec). Intubation
was not completed within 90 sec in 50/200 patients
under succinylcholine and 67/201 patients under rocur-
onium (P = 0.048). Qualitative scores of intubation con-
ditions are shown in Figure 4. The numerical sub-scores
for ease of laryngoscopy (succinylcholine 2.75 ± 0.45;
rocuronium 2.75 ± 0.46; P = 0.84) and conditions of the
vocal cords (succinylcholine 2.61 ± 0.52; rocuronium
2.67 ± 0.56; P = 0.32) did not differ between the groups
 
 
Assessed for eligibility (n= 579) 
Excluded (n = 159) 
i   Contraindication against RSI (n = 13) 
i   Contraindication against Suc-choline (n = 14 ) 
i   No study physician available (n = 132) ൺ5HJLVWU\ 
 
Analysed (n = 200) 
i Excluded from analysis (n = 8) 
8 dual inclusions ൺ Registry 
Lost to follow-up (n = 0) 
Allocated to succinylcholine (n = 210) 
i Received succinylcholine (n = 208) 
i Did not receive succinylcholine (n = 2) 
  2 cardiac arrests prior to RSI 
Lost to follow-up (n = 0) 
Allocated to rocuronium (n = 210) 
i Received rocuronium (n = 208) 
i Did not receive rocuronium (n = 2) 
  1 cardiac arrest prior to RSI 
  1 apnea prior to RSI  
Analysed (n = 201) 
i Excluded from analysis (n = 7) 
7 dual inclusions ൺ Registry 
Allocation 
Analysis 
Follow-Up 
Randomized (n = 420) 
Enrollment 
Figure 1 Patients’ flow diagram reported in CONSORT style. RSI, rapid sequence induction (intubation).
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sub-score of the response to intubation (succinylcholine
2.97 ± 0.20; rocuronium 2.86 ± 0.36; P =0 . 0 0 1 ) .T h e
overall numerical score for intubation conditions
(succinylcholine 8.3 ± 0.8; rocuronium 8.2 ± 0.9; P =
0.7) did not differ between the groups. There was no
difference between the groups in the incidence of hemo-
dynamic consequences of intubation (Table 4).
Discussion
During the course of an emergent intubation the inci-
dence and severity of oxygen desaturations did not differ
between critically ill patients undergoing RSI with succi-
nylcholine and those undergoing RSI with rocuronium
as the neuromuscular blocking agent. The mean intuba-
tion sequence was 14 sec shorter after succinylcholine
than after rocuronium. Succinylcholine and rocuronium
resulted in similar intubation conditions and a similar
incidence of intubation related complications.
A recent Cochrane Review demonstrated that for a
RSI succinylcholine created better intubation conditions
than rocuronium [3]. However, all patients included in
the Cochrane Review were intubated in the operating
theatre. Conditions in intensive care and in the emer-
gency department may differ in several important
aspects from those in the operating theatre (for example,
severity of patients’ illness, limited possibility to perform
a pre-intubation airway assessment, less ideal ergonomic
conditions) so that findings from one setting are not
necessarily applicable to the other. Particularly, the inci-
dence of relevant intubation-related complications is
very small in the operating theatre so that available stu-
dies are underpowered for these outcomes. In keeping
with previous work, the present study demonstrates that
emergent intubations in intensive care are associated
with a high rate of immediate and potentially life-threa-
tening complications like oxygen desaturations and
failed intubation attempts [4,5,15].
In contrast to the majority of studies performed in the
operating theatre [3], the present study demonstrated no
difference in intubation conditions between succinylcho-
line and rocuronium. In emergency department RSI,
Lauren et al. reported that succinylcholine resulted in
less body movements as a reaction to intubation than
rocuronium, while there was no difference between the
two drugs with regard to the degree of vocal cord move-
ments [16]. In emergent RSI in the operating theatre,
Sluga et al. reported that the difference in the overall
intubation scores between succinylcholine and rocuro-
n i u mw a se n t i r e l yd u et oad i f f e r e n c ei nt h es u b - s c o r e
assessing the intubation response, that is, limb move-
ments and/or coughing, while there was no difference in
the remaining sub-scores assessing the ease of laryngo-
scopy or the conditions of the vocal cords [9]. The pre-
vious finding of similar sub-scores for laryngoscopy and
vocal cords is confirmed by our results. As limb move-
ments and/or coughing were only rarely observed in the
present study, sub-scores for the intubation response
Table 2 Indications for emergent intubations in 401
critically ill patients
ICD-10 N
Respiratory indications for intubation (n = 264)
Respiratory failure due to sepsis A41 53
Pneumonia, hospital-acquired J13 to
J15
53
Pneumonia, community-acquired J13 to
J15
51
Respiratory failure ≤ 24 h after extubation J95.8 36
Exacerbation of COPD (chronic obstructive pulmonary
disease)
J44.0 22
Pulmonary oedema J81 10
ARDS (adult respiratory distress syndrome) J80 7
Aspiration of blood (n = 3) or gastric contents (n = 4) W78 7
Thoracic trauma S22 5
Pulmonary haemorrhage R04.8 4
Respiratory failure ≤ 24 h after self-extubation J96.0 4
Respiratory failure due to massive pulmonary secretion J96.0 4
Respiratory failure due to dislocation of a tracheal
cannula
J96.0 3
Pancreatitis K85 2
Pulmonary oedema due to inhalational trauma J68.1 1
Malignant neoplasm of larynx C32 1
Angioneurotic oedema of the tongue T78.3 1
Neurologic indications for intubation (n = 92)
Epilepsy and Status epilepticus with GCS ≤ 6 G40, G41 33
Hepatic coma with GCS ≤ 6 K72.0 9
Poisoning with GCS ≤ 6 T40, T42 9
Intracerebral haemorrhage with GCS ≤ 6 I61 7
Guillain-Barré syndrome G61.0 6
Cerebral infarction with GCS ≤ 6 I63 5
Coma of unknown origin with GCS ≤ 6 G93.9 5
Subarachnoidal haemorrhage with GCS ≤ 6 I62 4
Delirium F05 4
Myasthenia gravis G70.0 3
Cerebral venous throbosis with GCS ≤ 6 I63.6 2
Diabetic coma with GCS ≤ 6 E10.0 1
Encephalitis with GCS ≤ 6 G04 1
Meningitis with GCS ≤ 6 G00 1
Traumatic cerebral oedema with GCS ≤ 6 S06.1 1
Thrombotic thrombocytopenic purpura with GCS ≤ 6 M31.1 1
Shock as indication for intubation (n = 45)
Cardiogenic shock due to acute myocardial infarction I23.8 18
Cardiogenic shock due to acute non-ischaemic heart
disease
R57.0 7
Septic shock A41.9 13
Haemorrhagic shock R57.1 7
ICD categories relate to the current (2007) version of the WHO (World Health
Organisation).
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difference in the overall score for intubation conditions.
This absent response to intubation in the majority of
critically ill patients is most likely due to the severity of
the underlying illness. Based on the present results and
previous findings [9,16] we propose that the difference
Table 3 Demographics
Succinylcholine
(N = 200)
Rocuronium
(N = 201)
Registry
(N = 147)
Age (years) 60 ± 16 63 ± 14 59 ± 16
Sex (m:f) 114:86 112:89 94:54
Height (cm) 170 ± 8 170 ± 9 171 ± 10
Weight (kg) 73 ± 15 74 ± 19 74 ± 11
Apache II Score 21 ± 7 22 ± 7 21 ± 6
Underlying COPD 32 (16%) 30 (15%) 27 (13%)
28-day mortality 73 (37%) 82 (41%) 53 (36%)
Indication for intubation
Respiratory failure 134 (67%) 130 (65%) 91 (62%)
Neurology 42 (21%) 50 (25%) 41 (28%)
Shock 24 (12%) 21 (10%) 15 (10%)
Non-invasive ventilation prior to intubation 93 (47%) 85 (43%) 62 (42%)
Induction agent
Propofol 101 (50%) 94 (47%) 47 (32%)
Etomidate 99 (50%) 107 (53%) 67 (46%)
Other 33 (22%)
Neuromuscular blocking agent
Succinylcholine 78 (53%)
Rocuronium 44 (30%)
Other 25 (17%)
The registry includes patients who were intubated while the trial was recruiting but were not included in the trial due to the unavailability of a study physician
(n = 132) or had to be excluded from the trial due to dual inclusion (n = 15).
The observed 28-day mortality corresponds to the expected mortality as APACHE II scores of 21 and 22 predict a mortality of approximately 39% and 42%
respectively [10]. COPD, chronic obstructive pulmonary disease.
Figure 2 Intubating times. Kaplan-Meyer curve of the probability
of the completion of the endotracheal intubation sequence
including succinylcholine or rocuronium in patients successfully
intubated in the first attempt. The x-axis denotes the time interval
after the beginning of the injection of the induction drug. The
intubation sequence was defined to be completed upon the first
appearance of end-tidal carbon dioxide after intubation.
Figure 3 Oxygen saturations. Oxygen saturation (SpO2)o b t a i n e d
by pulsoxymetry at the beginning of the pre-oxygenation period
(Start), after completion of pre-oxygenation (Preox), and minimum
value at any time between the start of the induction sequence and
two minutes after the completion of the intubation respectively.
Data are the means ± SD. There was no statistically significant
difference between succinylcholine and rocuronium.
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line and rocuronium [3] results entirely from a differ-
ence in the response to intubation, an event occurring
after the completion of the intubation with marginal
relevance for patients’ safety. By contrast, succinylcho-
line and rocuronium do not differ in two aspects of
intubation conditions highly relevant for patients’ safety
- the ease of laryngoscopy and the conditions of the
vocal cords.
During emergent intubations in the operating theatre,
succinylcholine allowed for a 35 sec earlier completion
of the intubation sequence than rocuronium [9]. In the
present study involving critically ill patients, this favor-
able effect of succinylcholine was reduced to 14 sec, that
is, to approximately 15% of the total length of the intu-
bation sequence with rocuronium. In almost 40% of our
patients visible fasciculations had not occurred or had
not ceased within 45 sec after the injection of succinyl-
choline, and, according to study protocol, laryngoscopy
was started in these patients at the same time as in the
rocuronium group. To the best of our knowledge, a
delayed onset of succinylcholine-induced fasciculations
in critically ill patients has not been reported so far. As
severe illness may have a profound effect on the neuro-
muscular system [17] it is tempting to speculate that the
severity of underlying illness is responsible for the differ-
ence in the onset of fasciculations and, hence, the
reduced advantage of succinylcholine with regard to
rapid completion of the intubation sequence between
patients in the operating theatre and patients in inten-
sive care.
A limitation of this trial is the lack of a double-blind
design. However, masking the effects of drugs like succi-
nylcholine that have visible effects (fasciculations) is
inherently difficult. A RSI in critically ill patients is a
high-risk procedure requiring the full attention of an
appropriately trained physician. Since in our settings the
simultaneous achievement of perfect blinding and opti-
mal patient safety was not feasible, we opted for a sin-
gle-blind study design. Using experienced operators and
a checklist (containing all relevant aspects recently
found to decrease complications related to intubation in
intensive care [5]), every effort was made to protect the
patients’ safety. Thus, our results are not necessarily
generalisible to settings with less stringent procedural
guidelines and/or less experienced operators. Our find-
ings were obtained with an induction sequence of fenta-
nyl and propofol or etomidate and cannot be
extrapolated to other drugs and/or doses.
The dose of rocuronium was chosen based on the best
evidence available at the time of the design of the trial,
that is, the Cochrane Review of 2003 [2]: For the out-
come acceptable versus suboptimal intubating condi-
tions, this review revealed no significant difference
between succinylcholine and rocuronium at a dose of
0.6 to 0.7 mg/kg. Moreover, a sensitivity analysis within
the propofol induction group (n =6 4 0 )f o rd o s eo f
rocuronium used (0.6 to 0.7 mg/kg versus 0.9 to 1.0
mg/kg) demonstrated that dose did not alter intubating
conditions. Weighing the risk of prolonged neuromus-
cular blockade associated with higher doses of rocuro-
nium against the lack of convincing evidence of better
intubating conditions, we chose the smallest dose
Excellent Good Poor
0
25
50
75
100
Succinylcholine
Rocuronium
%
Figure 4 Intubating conditions. Intubation conditions during
rapid sequence induction intubation with succinylcholine or
rocuronium. The scoring system is explained in Table 1. There were
no significant differences between the two neuromuscular blocking
drugs.
Table 4 Incidence of complications other than oxygen
desaturation of emergent intubations in 401 critically ill
patients
Succinylcholine
(n = 200)
Rocuronium
(n = 201)
Failed first intubation attempt 32 (16%) 36 (18%)
Anatomical difficult airway* 10 (5%) 12 (6%)
Difficult laryngoscopy
§ 7 (3.5%) 5 (2.5%)
Oesophageal intubation 2 (1%) 2 (1%)
Equipment problems 1 (0.5%) 3 (1.5%)
Aspiration
† 4 (2%) 3 (1.5%)
Need of a vasopressor after intubation
¶ 84 (42%) 90 (45%)
Cardiac arrest 6 (3%) 4 (2%)
Ventricular fibrillation 2 (1%) 1 (0.5%)
Pulsless electrical activity 4 (2%) 3 (1.5%)
Asystole 0 0
Death 0 0
* An anatomically difficult airway was defined as more than two attempts or a
successful second attempt with the help of additional equipment (for
example, a different blade) or a modified technique (for example, preforming
a stylet).
§ Difficult laryngoscopy was defined as impaired vision of laryngeal structures
due to non-anatomical reasons (for example, blood or secretion).
† Blood, gastric content, or foreign body visible below the vocal cords during
laryngoscopy
¶ Need of vasopressor was defined as an intravenous bolus of a vasopressor
or an increase in infusion rate of a running catecholamine infusion.
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2008 update of the Cochrane Review demonstrated an
advantage of succinylcholine against lower (0.6 to 0.7
mg/kg), but not against higher (> 0.9 mg/kg), doses of
rocuronium for the outcome acceptable versus subopti-
mal intubating conditions [3]. As the difference is small
(risk ratio 0.95, 95% confidence intervals 0.90 to 0.99)
and, as extensively discussed above, appeared to be
mainly caused by the response to intubation [9], we
decided not to modify the protocol of our ongoing trial.
Our trial demonstrates identical intubating conditions
with 1 mg/kg succinylcholine and 0.6 mg/kg rocuro-
nium. Thus, in critically ill patients there is not an
advantage in choosing higher doses of rocuronium than
0.6 mg/kg.
Conclusions
The adverse effect profile of succinylcholine is of con-
cern and some authors even considered its use in the
ICU as obsolete [1]. Optimal intubation conditions
[2,3], a short intubation sequence [9], and the return
of spontaneous respiratory activity within 5 to 10 min-
utes are the main arguments of the proponents of the
use of succinylcholine in the ICU [18,19]. The present
study is the first formal comparison of succinylcholine
and rocuronium in an adequately powered randomized
controlled trial in critically ill patients. Our results
demonstrate that in emergent intubations in intensive
care 1) the incidence and severity of hypoxaemia does
not differ between rocuronium and succinylcholine; 2)
intubating conditions do not differ between rocuro-
nium and succinylcholine; 3) the advantage of succi-
nylcholine with regard to the length of the intubation
sequence is markedly reduced to a difference of ques-
tionable clinical significance; and 4) the incidence of
failed intubation attempts does not differ between
rocuronium and succinylcholine. Lee et al.r e p o r t e d
that the reversal of profound rocuronium-induced neu-
romuscular block with sugammadex was significantly
faster than spontaneous recovery from succinylcholine
[20]. Taking together its favourable safety profile, the
availability of a rapid-acting antagonist, and our pre-
sent results, rocuronium appears to be more than a
suitable alternative to succinylcholine for emergent RSI
intubations in acutely ill patients.
Key messages
■ This is the first formal comparison of succinylcho-
line and rocuronium for use in emergent rapid
s e q u e n c ei n d u c t i o ni n t u b a t i o ni ni n t e n s i v ec a r ei n
an adequately powered randomized controlled trial.
■ In critically ill patients, undergoing an emergent
rapid sequence induction intubation, the incidence
and severity of oxygen desaturations, the quality of
intubation conditions, and the incidence of failed
intubation attempts did not differ between succinyl-
choline and rocuronium.
Additional material
Additional file 1: Checklist of preparations to be performed prior to
RSI.
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